RLIP76, a Glutathione-Conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Singhal, Jyotsana ^a   Nagaprashantha, Lokesh ^a   Vatsyayan, Rit ^b   Awasthi, Sanjay ^a   Singhal, Sharad S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; ATORVASTATIN; CARRIER PROTEIN; CHOLESTEROL; FRUCTOSE 1,6 BISPHOSPHATE; GEMFIBROZIL; GLUCOSE; GLUCOSE 6 PHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; RAL INTERACTING PROTEIN 76; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; RALBP1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REGULATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; LIVER METABOLISM; METABOLIC SYNDROME X; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RECEPTOR UPREGULATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; DRUG ANTAGONISM; GENETICS; METABOLISM; MOUSE MUTANT; NUCLEIC ACID PROBE; PATHOPHYSIOLOGY;

MUS;

ANIMALS; ANTISENSE ELEMENTS (GENETICS); GEMFIBROZIL; GTPASE-ACTIVATING PROTEINS; HEPTANOIC ACIDS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; METABOLIC SYNDROME X; METFORMIN; MICE; MICE, KNOCKOUT; PYRROLES; THIAZOLIDINEDIONES;

EID: 80052725500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024688     Document Type: Article

References (54)

1. Awasthi S, Singhal SS, Yadav S, Singhal J, Vatsyayan R, et al. (2010) A central role of RLIP76 in regulation of glycemic control. Diabetes 59: 714-725.
2. Cefalu WT, (2008) Diabetic dyslipidemia and the metabolic syndrome. Diabetes Metab Syndrome 2: 208-222.
3. Fonseca MA, (2005) The metabolic syndrome, hyperlipidemia, and insulin resistance. Clinical Cornerstone 7: 61-72.
4. Puglianiello A, Cianfarani S, (2006) Central control of glucose homeostasis. Rev Diabetic Stud 3: 54-60.
5. Diehl AM, (2004) Fatty liver, hypertension, and the metabolic syndrome. Gut 53: 923-924.
6. Kurucz I, Morva A, Vaag A, Eriksson KF, Huang X, et al. (2002) Decreased expression of heat shock protein 72 in skeletal muscle of patients with type 2 diabetes correlates with insulin resistance. Diabetes 51: 1102-1109.
7. Jones TH, (2010) Effects of testosterone on type 2 diabetes and components of the metabolic syndrome. J Diabetes 2: 146-156.
8. Annaloro C, Usardi P, Airaghi L, Giunta V, Forti S, et al. (2008) Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplantation 31: 797-804.
9. Tenenbaum A, Fisman EZ, Motro M, (2003) Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovascular Diabetology 2: 4.
10. Ginsberg HN, MacCallum PR, (2009) The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr 4: 113-119.
11. Evans JL, Goldfine ID, Maddux BA, Grodsky GM, (2003) Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52: 1-8.
12. Talior I, Yarkoni M, Bashan N, Eldar-Finkelman H, (2003) Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice. Am J Physiol Endocrinol Metab 285: E295-302.
13. Tiedge M, Lortz S, Drinkgern J, Lenzen S, (1997) Relation between antioxidant enzyme gene expression and anti-oxidative defense status of insulin-producing cells. Diabetes 46: 1733-1742.
14. Jakoby WB, (1978) The glutathione S-transferases: A group of multifunctional detoxification proteins. Adv Enzymol Mol Biol 46: 383-414.
15. Hayes JD, Pulford DJ, (1995) The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemo-protection and drug resistance. Crit Rev Biochem Mol Biol 30: 445-600.
16. Evans JL, Maddux BA, Goldfine ID, (2005) The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 7: 1040-1052.
17. Maechler P, Jornot L, Wollheim CB, (1999) Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic beta cells. J Biol Chem 274: 27905-27913.
18. Sakai K, Matsumoto K, Nishikawa T, Suefuji M, Nakamaru K, et al. (2003) Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic beta-cells. Biochem Biophys Res Commun 300: 216-222.
19. Robertson RP, Harmon J, Tran POT, Poitout V, (2004) β-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 53: S119-S124.
20. Pessler D, Rudich A, Bashan N, (2001) Oxidative stress impairs nuclear proteins binding to the insulin responsive element in the GLUT4 promoter. Diabetologia 44: 2156-2164.
21. Krishnaswami A, Ravi-Kumar S, Lewis JM, (2010) Thiazolidinediones: A 2010 Perspective The Permanente Journal 14: 64-72.
22. Pollak M, (2010) Metformin and other biguanides in oncology: Advancing the research agenda. Cancer Prev Res 3: 1060-1065.
23. Awasthi S, Singhal SS, Sharma R, Zimniak P, Awasthi YC, (2003) Transport of glutathione conjugates and chemotherapeutic drugs by RLIP76 (RALBP1): a novel link between G-protein and tyrosine kinase signaling and drug resistance. Int J Cancer 106: 635-646.
24. Awasthi S, Singhal SS, Yadav S, Singhal J, Drake K, et al. (2005) RLIP76 is a major determinant of radiation sensitivity. Cancer Res 65: 6022-6028.
25. Singhal J, Singhal SS, Yadav S, Warnke M, Yacoub A, et al. (2008) RLIP76 in defense of radiation poisoning. Int J Rad Oncol Biol Phys 72: 553-561.
26. Singhal SS, Yadav S, Roth C, Singhal J, (2009) RLIP76: A novel glutathione-conjugate and multi-drug transporter. Biochem Pharmacol 77: 761-769.
27. Nagaprashantha L, Vatsyayan R, Singhal J, Lelsani P, Awasthi S, et al. (2011) 2′-Hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL mutant renal cell carcinoma. Carcinogenesis 32: 568-575.
28. Opie LH, Newsholme EA, (1967) The inhibition of skeletal-muscle fructose 1,6-diphosphatase by adenosine monophosphate. Biochem J 104: 353-360.
29. Taketa K, Pogell BM, (1965) Allosteric inhibition of rat liver fructose 1,6-diphosphatase by adenosine 5′-monophosphate. J Biol Chem 240: 651-662.
30. Gierow P, Jergil B, (1980) A spectrophotometric method for the determination of glucose-6-phosphatase activity. Anal Biochem 101: 305-309.
31. Singhal SS, Awasthi YC, Awasthi S, (2006) Regression of melanoma in a murine model by RLIP76 depletion. Cancer Res 66: 2354-2360.
32. Singhal SS, Singhal J, Yadav S, Dwivedi S, Boor P, et al. (2007) Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76. Cancer Res 67: 4382-4389.
33. Singhal SS, Yadav S, Singhal J, Sahu M, Awasthi YC, et al. (2009) RLIP76: A target for kidney cancer therapy. Cancer Res 69: 4244-4251.
34. Vatsyayan R, Lelsani P, Awasthi S, Singhal SS, (2010) RLIP76: A versatile transporter and an emerging target for cancer therapy. Biochem Pharmacol 79: 1699-1705.
35. Singhal SS, Wickramarachchi D, Yadav S, Singhal J, Leake K, et al. (2011) Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis. Mol Cancer Therapeutics 10: 16-28.
36. Han R, Lai R, Ding Q, Wang Z, Luo X, et al. (2007) Apolipoprotein A-I stimulates AMP-activated protein kinase and improves glucose metabolism. Diabetologia 50: 1960-1968.
37. Ding Q, Wang Z, Chen Y, (2009) Endocytosis of adiponectin receptor 1 through a clathrin- and Rab5-dependent pathway. Cell Res 19: 317-327.
38. Singhal SS, Yadav S, Drake K, Singhal J, Awasthi S, (2008) Hsf-1 and POB1 induce drug sensitivity and apoptosis by inhibiting Ralbp1. Hsf-1 and POB1 induce drug sensitivity and apoptosis by inhibiting Ralbp1. J Biol Chem 283: 19714-19729.
39. Singhal SS, Yadav S, Vatsyayan R, Chaudhary P, Borvak J, et al. (2009) Increased expression of Cdc2 inhibits transport function of RLIP76 and promotes apoptosis. Cancer Lett 283: 152-158.
40. Awasthi S, Cheng J, Singhal SS, Saini MK, Pandya U, et al. (2000) Novel function of human RLIP76: ATP-dependent transport of glutathione conjugates and doxorubicin. Biochemistry 39: 9327-9334.
41. Singhal SS, Sehrawat A, Mehta A, Sahu M, Awasthi S, (2009) Functional reconstitution of RLIP76 catalyzing ATP-dependent transport of glutathione-conjugate. Int J Oncol 34: 191-199.
42. Ikeda M, Ishida O, Hinoi T, Kishida S, Kikuchi A, (1998) Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral. J Biol Chem 273: 814-821.
43. Mäusera W, Perwitza N, Meiera B, Fasshauerb M, Kleina J, (2007) Direct adipotropic actions of atorvastatin: Differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake. Eur J Pharmacol 564: 37-46.
44. Jullien-Flores V, Dorseuil O, Romero F, Letourneur F, Saragosti S, et al. (1995) Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity. J Biol Chem 270: 22473-22477.
45. Rosse C, L'Hoste S, Offner N, Picard A, Camonis JH, (2003) RLIP, an effector of the Ral GTPases, is a platform for Cdk1 to phosphorylate epsin during the switch off of endocytosis in mitosis. J Biol Chem 278: 30597-30604.
46. Sharma R, Singhal SS, Wickramarachchi D, Awasthi YC, Awasthi S, (2004) RLIP76 (RALBP1) mediated transport of leukotrienes C4 (LTC4) in cancer cells: Implications in drug resistance. Int J Cancer 112: 934-942.
47. Tomkin GH, (2009) The effect of antidiabetic drugs on genes regulating lipid metabolism. Curr Opin Lipidology 20: 10-16.
48. Sanguino E, Ramón M, Michalik L, Wahli W, Alegret M, et al. (2004) Lack of hypo-triglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPAR alpha. Biochem Pharmacol 67: 157-166.
49. Belgardt BF, Mauer J, Brüning JC, (2010) Novel roles for JNK1 in metabolism. Aging 2: 621-626.
50. Belgardt BF, Mauer J, Wunderlich FT, Ernst MB, Pal M, et al. (2010) Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling coordinately regulates glucose metabolism. Proc Natl Acad Sci 107: 6028-6033.
51. Anisimov VN, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, et al. (2010) Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice. Aging 2: 945-958.
52. Anisimov VN, (2010) Metformin for aging and cancer prevention. Aging 2: 760-774.
53. Vetterli L, Maechler P, (2011) Resveratrol-activated SIRT1 in liver and pancreatic beta cells: a Janus head looking to the same direction of metabolic homeostasis. Aging 3: 444-449.
54. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, et al. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122.